An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting

CompletedOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions

Prevention of Thromboembolic EventsAtrial Fibrillation

Interventions

DRUG

Apixaban

No drug will be provided to participants. Patients follow routine clinical practice/administration.

Trial Locations (1)

Bayer, Whippany